TY - JOUR
T1 - Expression of 5'-nucleotidase (CD73) related to other differentiation antigens in leukemias of B-cell lineage
AU - Pieters, R.
AU - Thompson, L. F.
AU - Broekema, G. J.
AU - Huismans, D. R.
AU - Peters, G. J.
AU - Pals, S. T.
AU - Hahlen, K.
AU - Veerman, A. J.P.
PY - 1991
Y1 - 1991
N2 - Ecto-5' nucleotidase (5'NT; CD73) expression was studied with a monoclonal antibody (7G2) and a radiochemical assay and compared with the expression of other antigens in B-cell-lineage leukemias on cells from 100 leukemic patients and two cell lines. A B-cell origin was confirmed by the expression of CD19 and HLA-DR. Four stages of B-cell leukemias were defined: stage I (pro-B) as CD10-, cytoplasmic μ- (cμ-), surface Ig- (slg-); stage II (cALL) as CD10+/cμ-/slg-; stage III (pre-B) as CD10(+ or -)/cμ+/slg-; and stage IV (B) as CD10-/cμ-/slg+. A linear correlation was found between immunohistochemical and radiochemical determination of 5'NT (r = .86). 5'NT expression was low in T-cell leukemias and stage I, high in stages II and III, and low again in stage IV of B-cell leukemias. 5'NT expression was not related to cμ, CD20, CD21, CD22, CD34, and terminal deoxynucleotidyl transferase (TdT) expression, but was significantly related to CD10 and inversely related to κ/λ expression. However, the 5'NT activity in CD10+ leukemias (stages II and III) shows a very wide range. Within the group of CD10+ leukemias no differences were detected between 5'NT+ and 5'NT- cells in their expression of other B-cell antigens. We conclude that the place of 5'NT in leukemias corresponding to early stages of B-cell development has been characterized. 5'NT is expressed in CD10+ stages and decreases before the expression of slgs. Future studies should make clear whether a high expression of this enzyme in CD10+ stages is a normal maturation phenomenon or a malignant phenomenon.
AB - Ecto-5' nucleotidase (5'NT; CD73) expression was studied with a monoclonal antibody (7G2) and a radiochemical assay and compared with the expression of other antigens in B-cell-lineage leukemias on cells from 100 leukemic patients and two cell lines. A B-cell origin was confirmed by the expression of CD19 and HLA-DR. Four stages of B-cell leukemias were defined: stage I (pro-B) as CD10-, cytoplasmic μ- (cμ-), surface Ig- (slg-); stage II (cALL) as CD10+/cμ-/slg-; stage III (pre-B) as CD10(+ or -)/cμ+/slg-; and stage IV (B) as CD10-/cμ-/slg+. A linear correlation was found between immunohistochemical and radiochemical determination of 5'NT (r = .86). 5'NT expression was low in T-cell leukemias and stage I, high in stages II and III, and low again in stage IV of B-cell leukemias. 5'NT expression was not related to cμ, CD20, CD21, CD22, CD34, and terminal deoxynucleotidyl transferase (TdT) expression, but was significantly related to CD10 and inversely related to κ/λ expression. However, the 5'NT activity in CD10+ leukemias (stages II and III) shows a very wide range. Within the group of CD10+ leukemias no differences were detected between 5'NT+ and 5'NT- cells in their expression of other B-cell antigens. We conclude that the place of 5'NT in leukemias corresponding to early stages of B-cell development has been characterized. 5'NT is expressed in CD10+ stages and decreases before the expression of slgs. Future studies should make clear whether a high expression of this enzyme in CD10+ stages is a normal maturation phenomenon or a malignant phenomenon.
UR - http://www.scopus.com/inward/record.url?scp=0025787038&partnerID=8YFLogxK
U2 - 10.1182/blood.v78.2.488.bloodjournal782488
DO - 10.1182/blood.v78.2.488.bloodjournal782488
M3 - Article
C2 - 2070084
AN - SCOPUS:0025787038
SN - 0006-4971
VL - 78
SP - 488
EP - 492
JO - Blood
JF - Blood
IS - 2
ER -